is a simple blood test to aid detection and confirmation of HCC (hepatocellular carcinoma), in association with imaging, in high-risk patients with liver lesions of all sizes
- EarlyCDT-Liver is complementary to imaging for the diagnosis of HCC. The very high specificity of the test makes it a clinically useful “confirmation” test
- EarlyCDT-Liver detects HCC at all stages¹, with similar performance across all stages
- Its high specificity for early stage HCC (BCLC 0-B) can accelerate treatment and deliver improved patient outcomes
- The test complements all imaging modalities, providing confirmatory data
For nodules assessed by ultrasound alone, a High positive EarlyCDT-Liver
test result increases the risk of HCC by three to six times dependent on initial risk.
part of your workup of liver nodule malignancy risk assessment, and to detect cancers in surveillance more quickly.
Results are reported as High, Moderate or No Significant Level of Biomarkers detected. Only High and Moderate results are clinically actionable. The test rules-in, and does not rule-out, for HCC in liver lesions.
¹ Macdonald I et al. Development and Validation of an ELISA test detecting a panel of Autoantibodies in combination with AFP for Early Detection of Hepatocellular Carcinoma.